United States Oncology Regulatory Affairs Corporate Office — Nashville, Tennessee

Public research footprint of United States Oncology Regulatory Affairs Corporate Office, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Non-Small Cell Lung Cancer (NSCLC) · Metastatic Castration-resistant Prostate Cancer (mCRPC) · Advanced Solid Tumors · KRAS p, G12c Mutated /Advanced Metastatic NSCLC

Recently updated registry entries

NCT05920356 — A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum… (Recruiting)
NCT07213674 — A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With… (Recruiting)
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at United States Oncology Regulatory Affairs Corporate Office?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 05, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.